Silexion Therapeutics Corp
For the period ended Dec 31, 2025. Filed Mar 17, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 17, 2026
SLXN$0.12-14.7%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| 2025 | 2024 | |
|---|---|---|
| Assets | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $5,991 | $1,187 |
| Restricted cash | 27 | 35 |
| Prepaid expenses | 570 | 966 |
| Other current assets | 49 | 62 |
| TOTAL CURRENT ASSETS | 6,637 | 2,250 |
| NON-CURRENT ASSETS: | ||
| Restricted cash | 57 | 48 |
| Long-term deposit and other non-current assets | 84 | 5 |
| Property and equipment, net | 25 | 30 |
| Operating lease right-of-use asset | 412 | 530 |
| TOTAL NON-CURRENT ASSETS | 578 | 613 |
| TOTAL ASSETS | $7,215 | $2,863 |
F - 3
CONSOLIDATED BALANCE SHEETS
| 2025 | 2024 | |
|---|---|---|
| Liabilities and shareholders’ equity (capital deficiency) | ||
| CURRENT LIABILITIES: | ||
| Trade payables | $787 | $929 |
| Current maturities of operating lease liability | 182 | 158 |
| Employee related obligations | 879 | 642 |
| Other accounts payable | 910 | 788 |
| Private warrants to purchase ordinary shares (including $* and $1 due to related party, as of December 31, 2025 and December 31, 2024, respectively) | * | 2 |
| Underwriters Promissory Note | - | 1,004 |
| TOTAL CURRENT LIABILITIES | 2,758 | 3,523 |
| NON-CURRENT LIABILITIES: | ||
| Long-term operating lease liability | 286 | 368 |
| Related Party Promissory Note | 1,568 | 2,961 |
| TOTAL NON-CURRENT LIABILITIES | $1,854 | $3,329 |
| TOTAL LIABILITIES | $4,612 | $6,852 |
| COMMITMENTS AND CONTINGENT LIABILITIES (Note 7) | ||
| SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY): Ordinary shares ($0.0135 par value per share, 9,000,000 and 1,481,482 shares authorized as of December 31, 2025 and December 31, 2024, respectively; 3,126,651 and 123,290** shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively) | 42 | 2 |
| Additional paid-in capital | 57,727 | 39,263 |
| Accumulated deficit | (55,166) | (43,254) |
| TOTAL SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) | $2,603 | $(3,989) |
| TOTAL LIABILITIES AND SHAREHOLDERS' EQUITY (CAPITAL DEFICIENCY) | $7,215 | $2,863 |
All share amounts have been retroactively adjusted to reflect a 1-for-15 reverse share split as discussed in Note 1(e)
**Net of 28 treasury shares held by the Company as of December 31, 2024
F - 4
CONSOLIDATED STATEMENTS OF OPERATIONS
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.